| FINANCING OF PRIVATE BIOTECHNOLOGY COMPANIES: $124.23M | ||||
Company |
Location |
Date |
Amt. (M) |
Details |
Aldagen Inc. |
Durham, N.C. |
12/19/06 |
$17.3 |
A $14.3M Series C financing was co-led by Harbert Venture Partners LLC and Intersouth Partners, and included Aurora Funds, Trelys Funds LP, Tall Oaks Capital, Village Ventures and the Piedmont Angel Network; a $3M debt financing was provided by Square 1 Bank |
Cardioxyl |
Towson, Md. |
12/6/06 |
$14.5 |
The Series A financing was co-led by The Aurora Funds and New Enterprise Associates |
Codon |
Cambridge, |
12/18/06 |
$20 |
The Series B financing was led by Highland Capital Partners and included previous investors Alloy Ventures, Flagship Ventures, Khosla Ventures and Kleiner Perkins Caufield & Byers |
ConjuGon |
Madison, Wis. |
12/13/06 |
$3.3 |
Rosetta Partners led the financing round, which included an additional investment by the Wiscon- sin Investment Partners |
Cylex Inc. |
Columbia, Md. |
12/4/06 |
$18 4 |
Channel Medical Partners and Canaan Partners co-led what was expected to be the first closing of a Series C round; First Analysis and existing investors Cahn Medical Technologies, Calvert Venture Fund, Chesapeake Emerging Opportunities, Early Stage Enterprises, NJTC Venture Fund, Roche Venture Fund and The Washington Dinner Club also participated |
Genfit SA |
Lille, France |
12/12/06 |
€15 |
The financing was completed prior to admission of the company's shares on the Euronext market; it sold 1.67M shares; the reference share price upon listing was €9, with 11.27M shares outstanding |
Morphogenesis |
Oldsmar, Fla. |
12/4/06 |
£0.193 ($0.38) |
The investment was provided by ValiRx plc, which also received three-year warrants in the deal |
Predictive |
Lexington, Mass. |
12/18/06 |
$10 |
The Series A financing was co-led by Highland Capital Partners and IDG Ventures Boston |
Provid |
North Brunswick, N.J. |
12/19/06 |
$0.75 |
The funding was provided by the Edison Innovation Fund |
VIRxSYS |
Gaithersburg, |
12/13/06 |
$20 |
The Series G round of financing came from the exercise of warrants from investors in the com- pany's October 2005 $31M Series F round |
Notes: | ||||
Currency conversions are based on exchange rates at the time of the deal. | ||||
ND = Not disclosed. | ||||
To read more on related topics, click on one of the words below.